熱門資訊> 正文
Maze Therapeutics在1.5亿美元的股票发行上上涨
2025-09-11 19:45
- Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds of approximately $150.0 million.
- The offering includes 4,000,002 shares at $16.25 each, a premium to the last closing price. In lieu of common stock, certain investors purchased 5,231,090 pre-funded warrants at a purchase price of $16.249 per pre-funded warrant.
- The offering is expected to close on September 12, 2025, pending customary conditions.
- Maze will use the proceeds, along with existing cash, to advance its drug pipeline, including the development of MZE829 in patients with APOL1-mediated kidney disease, MZE782 in both phenylketonuria and chronic kidney disease, as well as to support research, its Compass platform, and general corporate purposes.
- Source: Press Release
More on Maze Therapeutics
- Historical earnings data for Maze Therapeutics
- Financial information for Maze Therapeutics
推薦文章
港股周報丨阿里重磅利好！周內暴漲14%；北水單周淨買入港股608億港元環比驟增8成
一周財經日曆 | 萬衆矚目！9月美聯儲利率決議來襲；三隻港股新股即將上市
美股機會日報 | 金價年內或觸及3800美元？國際大行集體唱多黃金！超微電腦漲超5%
能否趕上美聯儲下周議息會議？美參院就米蘭理事提名錶決時間定了
港股異動 | 重磅利好！阿里漲近7%，百度漲超6%
華盛早報 | 創近4年新高！阿里大漲8%；外資熱情勢不可擋！大摩：超九成美國投資者願加倉中國資產
美股機會日報 | 美國8月CPI符合預期，初請失業金人數創近四年新高！「網紅股」Opendoor股價大漲超30%
萬億南向「活水」瘋狂搶籌！重倉阿里巴巴逾1200億港元，如何抄「聰明錢」的作業？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
